Loading...
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered role...
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234358/ https://ncbi.nlm.nih.gov/pubmed/30425065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020065 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|